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Summary	5	
Bone	mineral	density	declines	with	increasing	older	age.	We	examined	the	levels	of	6	
circulating	factors	known	to	regulate	bone	metabolism	in	healthy	young	and	older	adults.	7	
The	circulating	levels	of	dickkopf-1,	osteocalcin,	osteoprotegerin	and	sclerostin	were	8	
positively	associated	with	WBMD	in	older	adults,	despite	the	average	WBMD	being	lower	9	
and	circulating	dickkopf-1,	osteoprotegerin	and	sclerostin	being	higher	in	old	than	young.			10	
	 	11	
	 3	
Abstract	1	
Purpose:	To	investigate	the	relationship	between	whole-body	bone	mineral	density	2	
(WBMD)	and	levels	of	circulating	factors	with	known	roles	in	bone	remodelling	during	3	
‘healthy’	ageing.	4	
Methods:	WBMD	and	fasting	plasma	concentrations	of	dickkopf-1,	fibroblast	growth	factor-5	
23,	osteocalcin,	osteoprotegerin,	osteopontin	and	sclerostin	were	measured	in	272	older	6	
subjects	(69	to	81	years;	52%	female)	and	171	younger	subjects	(18-30	years;	53%	female).		7	
Results:		WBMD	was	lower	in	old	than	young.	Circulating	osteocalcin	was	lower	in	old	8	
compared	with	young,	while	dickkopf-1,	osteoprotegerin	and	sclerostin	were	higher	in	old	9	
compared	with	young.		These	circulating	factors	were	each	positively	associated	with	10	
WBMD	in	the	older	adults	and	the	relationships	remained	after	adjustment	for	covariates	(r-11	
values	ranging	from	0.174	to	0.254,	all	p<0.01).	In	multivariate	regression,	the	body	mass	12	
index,	circulating	sclerostin	and	whole-body	lean	mass	together	accounted	for	13.8%	of	the	13	
variation	with	WBMD	in	the	older	adults.	In	young	adults,	dickkopf-1	and	body	mass	index	14	
together	accounted	for	7.7%	of	variation	in	WBMD.	15	
Conclusion:	Circulating	levels	of	dickkopf-1,	osteocalcin,	osteoprotegerin	and	sclerostin	are	16	
positively	associated	with	WBMD	in	community-dwelling	older	adults,	despite	the	average	17	
WBMD	being	lower	and	circulating	dickkopf-1,	osteoprotegerin	and	sclerostin	being	higher	18	
in	old	than	young.	19	
	20	
21	
	 4	
Introduction	1	
Progressive	loss	of	bone	mineral	density	(BMD)	in	older	age	leads	to	osteoporosis	as	the	2	
balance	of	bone	remodelling	favours	resorption	of	mineralised	extracellular	matrix	over	3	
formation.	This	common	change	is	characterized	by	‘micro-architectural’	deterioration	of	4	
bone	tissue	and	increases	the	risk	of	fracture	[1].	Circulating	factors	influencing	bone	5	
development	have	been	implicated	in	the	age-related	changes	to	BMD.	This	includes	6	
regulatory	factors	released	from	osteoblasts	and	osteocytes	involved	in	bone	formation	and	7	
from	osteoclasts	with	bone	resorption,	which	can	enter	the	circulation	where	their	8	
concentrations	may	be	related	to	BMD	in	older	age.	9	
Some	of	the	candidate	circulating	factors	possibly	related	to	BMD	include	osteoprotegerin	10	
(OPG),	which	is	expressed	by	osteocytes	and	osteoblasts	and	can	reduce	production	of	11	
osteoclasts	by	binding	receptor	activator	of	nuclear	factor	kappa-B	ligand	(RANKL)	[2].	12	
Osteocalcin	(OC)	is	a	major	non-collagen	protein	of	the	bone	matrix	secreted	by	osteoblasts	13	
for	bone	formation,	but	released	from	the	matrix	during	bone	resorption	[3].	Dickkopf-1	14	
(DKK1)	[4]	and	sclerostin,	released	primarily	by	osteocytes	[5],	negatively	regulate	bone	15	
formation	and	have	emerged	as	therapeutic	targets	to	tackle	osteoporosis	[6].	Fibroblast	16	
growth	factor	23	(FGF23)	is	produced	by	a	variety	of	cell	types,	including	osteoblasts	and	17	
osteocytes,	and	released	into	the	circulation	where	it	acts	on	the	kidney	to	increase	18	
excretion	of	phosphate	and	reduce	production	of	1-25	OH	Vitamin	D	[7].	Osteopontin	(OPN)	19	
is	an	extracellular	matrix	protein	released	by	osteoblasts,	osteocytes	and	osteoclasts	to	20	
facilitate	bone	resorption	[8].		21	
It	remains	unclear	how	the	combination	of	these	circulating	markers	of	bone	turnover	are	22	
related	to	BMD	in	older	age.	Therefore,	the	purpose	of	this	study	was	to	compare	plasma	23	
concentrations	of	these	markers	between	recreationally	active,	community	dwelling	older	24	
adults	and	a	reference	group	of	young	adults,	and	to	examine	the	association	of	these	with	25	
whole-body	bone	mineral	density	(WBMD).	It	was	hypothesised	that	older	adults	would	26	
have	higher	circulating	levels	of	factors	related	to	bone	resorption	compared	with	young,	27	
and	higher	circulating	markers	of	bone	resorption	were	expected	to	be	associated	with	28	
lower	BMD	in	old	age.		29	
	30	
	 5	
Materials	and	Methods	1	
Study	Design	2	
The	cross-sectional	European	multi-centre	MYOAGE	cohort	consists	of	relatively	healthy	3	
older	men	and	women	(aged	69	to	81	years)	and	young	adults	(aged	18-30	years)	[9].	The	4	
study	was	approved	by	ethics	committees	at	each	institute	and	written	informed	consent	5	
was	obtained	from	all	participants.	Participants	were	recruited	by	advertisement	in	6	
newspapers,	the	University	of	the	Third	Age	and	Association	of	Emerti.	All	measurements	7	
were	performed	according	to	standard	operating	procedures	that	had	been	unified	at	the	8	
study	centres	and	data	collection	was	ceased	through	December-March	and	July-August.	9	
Volunteers	were	excluded	if:	dependent	living,	unable	to	walk	a	distance	of	250	m,	presence	10	
of	morbidity	(such	as	neurologic	disorders,	metabolic	diseases,	rheumatic	diseases,	heart	11	
failure,	severe	chronic	obstructive	pulmonary	disease	and	hemocoagulative	syndromes),	12	
immobilization	for	one	week	during	the	last	three	months	and	orthopaedic	surgery	during	13	
the	last	two	years	or	still	causing	pain	or	functional	limitations.	The	inclusion	and	exclusion	14	
criteria	were	designed	to	ensure	the	selection	of	relatively	healthy	participants	and	to	15	
minimize	the	confounding	effect	of	comorbidity	on	sarcopenia	[9]	and	we	recorded	the	use	16	
of	bisphosphonates,	calcium	and	vitamin	D	supplements.	The	present	study	included	443	17	
participants	(Leiden,	The	Netherlands	(young;	n=35,	old;	n=75);	Jyvaskyla,	Finland	(young;	18	
n=34,	old;	n=65);	Tartu,	Estonia	(young;	n=39,	old;	n=60),	Paris,	France	(young;	n=35,	old;	19	
n=30)	and	Manchester,	UK	(young;	n=28,	old;	n=42))	with	complete	BMD	and	bloods	results.	20	
	21	
Dual-energy	X-ray	absorptiometry	22	
A	whole	body	scan	was	performed	using	DXA	while	the	participants	lay	supine,	as	previously	23	
reported	[9]	(The	Netherlands:	Hologic	QDR	4500,	version	12.4,	Hologic	Inc.,	Bedford,	MA,	24	
USA;	Finland:	Lunar	Prodigy,	version	en-Core	9.30;	Estonia:	Lunar	Prodigy	Advanced,	version	25	
en-Core	10.51.006;	France:	Lunar	Prodigy,	version	encore	12.30;	United	Kingdom:	Lunar	26	
Prodigy	Advance,	version	enCore	10.50.086).	A	trained	technician	completed	the	daily	27	
equipment	calibration	and	the	DXA	scans	according	to	local	and	manufacturers’	quality	28	
control	procedures.	Participants	wore	a	light	cotton	garment	to	reduce	effects	of	clothing	29	
absorption	on	the	scanning	results.	The	whole-body	lean	mass,	fat	mass	and	the	WBMD	30	
were	recorded	after	manual	adjustment	of	the	regions	of	interest	carried	out	offline.	31	
	 6	
	1	
Blood	sample	analysis	2	
Blood	samples	were	collected	from	a	vein	in	the	forearm	into	vacutainer	EDTA	tubes	in	the	3	
morning	when	participants	were	in	a	fasted	state.	Samples	remained	at	room	temperature	4	
for	15-30	min	and	were	then	centrifuged	for	15	min	at	2,000	*g	at	4◦	C.	The	plasma	was	5	
collected	and	stored	at	-80◦C	until	analysis.	Plasma	concentrations	of	the	selected	analytes	6	
were	determined	in	the	research	laboratory	in	Manchester,	UK,	using	multiplex	7	
immunoassays	(Millipore,	Billerica,	MA,	USA).		The	manufacturer	instructions	were	followed	8	
and	the	magnetic	bead	panels	quantified	DKK1,	OPG,	OC,	OPN,	sclerostin	and	FGF23	using	a	9	
96-well	plate	after	an	overnight	incubation.	The	sensitivity	of	each	analyte	was	1.4	(DKK1),	10	
1.9	(OPG),	68.5	(OC),	37.7	(OPN),	31.1	(sclerostin)	and	9.2	(FGF23)	pg/mL.	Samples	were	11	
processed	using	a	Luminex	200	Bioanalyser	and	protein	concentrations	were	estimated	12	
using	the	xPONENT	software	(Luminex,	v.3.1.871).	13	
	14	
Statistical	analysis	15	
Participant	descriptive	characteristics	(Table	1)	were	normally	distributed	and	are	presented	16	
as	mean	±	standard	error	of	the	mean	(SEM).	Comparisons	between	age	and	gender	were	17	
assessed	using	multivariate	ANOVA.	Relationships	between	body	stature,	BMI,	total	body	18	
lean	mass	and	supplement	use	(independent	variables)	with	WBMD	(dependent	variable)	19	
were	assessed	using	bivariate	Pearson’s	product	moment	correlation.	Data	for	circulating	20	
factors	were	not	normally	distributed	and	are	presented	as	median	(25th/75th)	centiles.	The	21	
results	were	log-transformed	and	z-scores	calculated	by	expressing	each	log-transformed	22	
value	as	a	standard	deviation	from	the	mean	of	the	gender-matched	young.	Z-scores	of	23	
WBMD,	lean	mass	and	BMI	were	also	calculated	for	use	in	subsequent	correlation	and	24	
regression	analysis.	Spearman’s	rho	partial	correlations	were	performed	to	assess	25	
relationships	between	the	z-score	WBMD	with	z-scores	of	circulating	factors	using	two	26	
models.	The	first	model	included	adjustment	for	country	of	testing	to	account	for	any	27	
systematic	differences.	The	second	accounted	for	the	positive	correlations	we	observed	28	
between	WBMD	and	BMI	in	men	and	women	(r-values	ranging	from	0.210	–	0.387)	and	29	
WBMD	and	lean	mass	for	men	(r-values	in	men	ranging	from	0.268	–	0.357,	and	women	30	
0.085	–	0.099)	as	well	as	health	status	and	use	of	bisphosphonates,	calcium	or	vitamin	D	31	
	 7	
supplements.	Thus,	the	second	model	included	adjustments	for:	country	of	testing,	z-score	1	
of	lean	mass,	z-score	of	BMI,	self-reported	health	and	supplement	use.	A	stepwise	multiple	2	
linear	regression	using	the	self-reported	health	and	supplement	use	as	well	as	z-scores	for	3	
BMI,	lean	mass	and	circulating	factors	was	then	used	to	evaluate	which	combination	of	the	4	
independent	variables	was	associated	with	z-score	WBMD	(dependent	variable)	in	older	5	
adults	and	in	young	adults.	Data	was	analysed	using	SPSS	for	Windows	(v.21;	IBM,	USA)	and	6	
significance	accepted	as	p<0.05.	7	
	8	
Results	9	
Based	on	z-scores	relative	to	gender-matched	young,	26%	of	the	older	participants	had	10	
WBMD	values	between	-1.5	to	-2.49	below	the	mean	for	young	and	10.6%	were	≥	-2.5	11	
below	the	mean	of	young.	There	was	a	significant	age-by-gender	interaction	for	WBMD	z-12	
scores	(p<0.0005).	13	
Table	2	shows	concentrations	of	the	circulating	factors.	Compared	with	young,	older	14	
participants	had	higher	concentrations	of	DKK1,	OPG	and	sclerostin.	Concentrations	of	OC	15	
were	significantly	lower	in	old	compared	with	young.	OPN	and	FGF23	did	not	differ	16	
significantly	between	young	and	older	participants	although	this	was	after	removal	of	37%	17	
of	FGF23	samples	[similar	proportions	of	young	and	old]	that	fell	below	the	level	of	assay	18	
detection.	Compared	with	men,	women	had	higher	circulating	concentrations	of	OPG,	but	19	
lower	OPN	and	sclerostin.	There	were	no	significant	differences	between	men	and	women	20	
for	DKK1,	FGF23	and	OC.	Age	x	gender	interactions	were	found	for	OC,	OPG	and	sclerostin	21	
(all	p<0.05):	the	difference	between	young	and	old	in	OC,	OPG	and	sclerostin	was	greater	for	22	
men	than	it	was	for	women.	23	
Table	3	shows	the	associations	between	circulating	bone	regulatory	factors	and	WBMD.	24	
When	using	z-scores	of	all	variables	and	including	all	participants,	while	adjusting	for	25	
country,	WBMD	was	positively	associated	with	DKK1.	This	association	remained	significant	26	
after	additionally	adjusting	for	lean	mass,	BMI,	self-reported	health	and	supplement	use.	In	27	
older	participants	only,	DKK1,	OC,	OPG	and	sclerostin	were	positively	associated	with	28	
WBMD	after	adjusting	for	country.	This	remained	the	case	when	additionally	adjusting	for	29	
lean	mass,	BMI,	self-reported	health	and	supplement	use.	In	younger	participants	only,	30	
	 8	
DKK1	was	positively	associated	with	WBMD	after	adjusting	for	country	as	well	as	when	1	
additionally	adjusting	for	lean	mass,	BMI,	self-reported	health	and	supplement	use.	2	
Stepwise	multiple	linear	regression	was	performed	including	z-score	WBMD	as	the	3	
dependent	variable	and	independent	variables	included:	self-reported	health,	supplement	4	
use	and	z-scores	of	the	variables	BMI	and	lean	mass,	as	well	as	the	z-scores	derived	from	5	
log-transformed	data	for	DKK1,	FGF23,	OC,	OPG,	OPN	and	sclerostin.	Results	in	the	young	6	
showed	DKK1	accounted	for	5.1%	of	the	variation	in	WBMD	(adjusted	r2=0.051,	p=0.010),	7	
while	DKK1	and	BMI	accounted	for	7.7%	of	the	variation	in	WBMD	(adjusted	r2=0.077,	8	
p=0.005).	In	the	old,	BMI	alone	accounted	for	8.9%	of	the	variation	in	WBMD	(adjusted	9	
r2=0.089,	p<0.0005);	BMI	and	sclerostin	together	accounted	for	12.0%	of	the	variation	in	10	
WBMD	(adjusted	r2=0.120,	p<0.0005),	while	BMI,	sclerostin	and	whole	body	lean	mass	11	
accounted	for	13.8%	of	the	variation	in	WBMD	(adjusted	r2=0.138,	p<0.0005).	12	
	13	
	14	
Discussion	15	
The	results	of	this	study	showed	that	circulating	factors	DKK1,	OPG	and	sclerostin	were	each	16	
higher	in	old	compared	with	young,	but	positively	associated	with	WBMD	in	older	adults.	17	
Circulating	OC	was	lower	in	old	compared	with	young	and	positively	associated	with	WBMD.	18	
In	multivariate	regression,	BMI,	circulating	sclerostin	and	whole-body	lean	mass	together	19	
accounted	for	13.8%	of	the	variation	with	WBMD	in	the	older	adults.	In	young,	DKK1	and	20	
BMI	together	accounted	for	7.7%	of	variation	in	WBMD.		21	
Circulating	factors	associated	with	whole-body	BMD	22	
Five	out	of	the	six	circulating	factors	differed	in	concentration	between	old	and	young	(Table	23	
2).	Of	those,	DKK1,	OC,	OPG	and	sclerostin	were	identified	from	both	partial	correlation	24	
models	as	associated	with	WBMD	in	older	participants	(Table	3).	25	
Sclerostin	and	DKK1	are	released	primarily	by	osteocytes	and	inhibit	bone	formation	by	26	
blocking	the	osteoblast	Wnt/β-canenin	signalling	pathway	[4,	10],	with	sclerostin	and	DKK1	27	
also	stimulating	bone	resorption	through	RANKL	[11].	Down-regulation	of	sclerostin	[6]	and	28	
DKK1	[4,	6]	is	associated	with	markedly	increased	bone	formation.	For	these	reasons,	an	29	
	 9	
inverse	association	between	circulating	sclerostin	and	DKK1	with	WBMD	would	be	expected,	1	
but	is	not	entirely	what	was	observed.	In	line	with	expectations,	our	results	revealed,	on	2	
average,	a	1.8	fold	higher	circulating	sclerostin	and	approximately	1.2-fold	higher	DKK1	in	3	
old	compared	with	young,	which	is	consistent	with	an	inverse	association	between	4	
sclerostin	and	BMD	in	older	age	[12]	and	with	results	from	a	small	sample	of	36	patients	5	
showing	an	inverse	association	between	DKK1	and	lumbar	and	femur	BMD	[13].	However,	6	
contrary	to	expectations,	the	circulating	levels	of	sclerostin	and	DKK1	were	positively	7	
associated	with	WBMD	in	the	older	participants	(Table	3).	Similar	positive	associations	8	
between	circulating	sclerostin	with	BMD	and	bone	micro-architecture	in	old	age	has	been	9	
previously	reported	[14-17].		10	
Similar	to	the	findings	for	sclerostin	and	DKK1,	a	paradoxical	relationship	existed	for	OPG	11	
and	WBMD	in	older	adults:	we	found	higher	circulating	OPG	in	old	compared	with	young	12	
(Table	2),	but	circulating	OPG	was	positively	associated	with	WBMD	(Table	3).	OPG	released	13	
by	osteocytes	and	osteoblasts	promotes	bone	formation.	It	has	been	shown	to	protect	14	
against	generalised	bone	resorption	by	blocking	TNFα	in	models	of	chronic	inflammation	15	
[18]	and	is	considered	to	be	a	decoy	receptor	for	RANKL	to	reduce	osteoclast-driven	bone	16	
resorption	[19].	There	are	conflicting	reports	about	the	direction	of	association	between	17	
circulating	OPG	and	BMD.	A	study	of	postmenopausal	women	of	mean	age	62	years	[20],	18	
and	a	study	of	middle	aged	men	[21]	reported	inverse	relationships	between	BMD	and	OPG,	19	
while	others	reported	no	relationship	[22,	23].	Conversely,	and	in	line	with	the	results	of	the	20	
present	work,	when	adults	in	their	eighth	and	ninth	decades	of	life	were	included	in	the	21	
sample	population	the	relationship	between	OPG	and	BMD	was	positive	[24,	25].	These	22	
conflicting	results	cannot	be	explained	by	the	differences	between	studies	in	skeletal	site	23	
examined.	Conflicting	results	may	be	related	to	the	differences	in	the	age	range	of	the	study	24	
samples	and	possible	gender	differences.	Our	results	for	OPG	and	sclerostin	showed	25	
significant	age	x	gender	interactions	indicating	that	the	differences	between	young	and	26	
older	men	were	greater	than	those	between	young	and	older	women	(Table	2).	It	is	already	27	
known	that	sex	hormones	can	regulate	bone	turnover	and	may	interact	with	these	28	
circulating	factors	[26].	29	
It	is	not	clear	why	circulating	sclerostin,	DKK1	and	OPG	were	positively	associated	with	30	
WBMD	in	older	age,	despite	the	conflicting	overall	trend	for	higher	circulating	levels	and	31	
	 10	
lower	WBMD	in	the	old.	One	possibility	is	that	the	older,	but	healthy	mature	osteocytes	1	
generally	release	higher	absolute	levels	of	sclerostin,	DKK1	and	OPG	into	the	circulation	[27]	2	
[28].	For	example,	a	positive	correlation	was	found	for	circulating	sclerostin	with	trabecular	3	
density,	number	and	thickness	in	older	men	[14,	27],	suggesting	the	more	advanced	4	
trabecular	resorption	in	osteoporotic	bone	leaves	fewer	mature	osteocytes	and	thus,	lower	5	
sclerostin	release	than	healthy	older	bone.	However,	analysis	of	bone	biopsies	showed	6	
similar	sclerostin	mRNA	levels	in	young	and	old	despite	higher	circulating	sclerostin	levels	in	7	
the	old	[12]	which	indicates	that	the	age-related	differences	in	circulating	sclerostin	may	not	8	
be	due	to	increased	osteocyte	sclerostin	gene	expression,	although	this	does	not	necessarily	9	
equal	protein	production	[29].		10	
Lower	circulating	OC	was	found	in	old	compared	with	young	(Table	2)	and,	consistent	with	11	
this,	circulating	OC	levels	were	positively	correlated	with	WBMD	in	the	old	(Table	3).	OC	12	
released	by	osteoblasts	plays	a	role	in	bone	formation,	so	the	positive	correlation	with	13	
WBMD	may	be	expected.	However,	others	suggest	that	higher	circulating	OC	indicates	14	
greater	rates	of	bone	resorption	because	fragments	or	whole	OC	protein	is	released	into	the	15	
circulation	during	bone	resorption	[3].	A	previous	study	of	young	and	middle-aged	women	16	
suggested	that	circulating	levels	peaked	soon	after	menopause	and	dropped	thereafter,	17	
although	levels	were	higher	in	those	with	osteoporosis	than	those	without	[30].	18	
Interestingly,	our	results	also	showed	a	positive	association	between	DKK1	and	WBMD	in	19	
the	young	adults	from	univariate	and	multivariate	analyses.	This	association	may	be	a	20	
reflection	of	the	numbers	of	mature	osteocytes	or	related	to	total	bone	mass,	but	more	21	
work	is	needed	to	confirm.	One	previous	study	of	children	and	adolescents	did	not	find	any	22	
association	between	circulating	DKK1	and	BMD,	but	the	young	included	in	that	study	of	23	
youths	were	in	stages	of	rapid	developmental	growth,	which	could	present	different	results	24	
from	the	steady-	state	of	young	adults	[31].		25	
	26	
Strengths	and	limitations	27	
The	MYOAGE	study	included	young	and	older	participants	relatively	free	from	lifestyle-28	
related	comorbidities	for	their	age	and	the	results	are	therefore	indicative	of	age-related	29	
effects.	Nevertheless,	the	associations	identified	in	this	cross-sectional	study	cannot	be	30	
interpreted	as	causal	relationships	despite	the	clear	roles	for	the	selected	circulating	31	
	 11	
markers	in	bone	remodelling.	The	results	for	FGF23	showed	no	significant	age-	or	gender-1	
differences,	nor	correlations	with	WBMD,	but	a	large	proportion	of	the	results	were	below	2	
the	level	of	assay	sensitivity,	so	firm	conclusions	cannot	be	drawn	for	this	analyte.	We	have	3	
measured	the	circulating	levels	of	markers,	which	may	be	influenced	by	release	from	non-4	
bone	cells,	so	it	is	not	possible	to	determine	the	originating	cell	type.	It	is	possible	that	5	
altered	renal	function	can	affect	the	levels	of	the	circulating	factors,	but	markers	of	renal	6	
function	was	not	included	in	the	present	study	due	to	limitation	of	plasma	sample	quantity.	7	
A	phantom	was	not	used	to	calibrate	the	DXA	scanners	across	sites	and	we	did	not	adjust	8	
the	results	to	derive	“standardised”	DXA	values,	as	others	have	done	for	hip	and	femur	sites	9	
[32].	Instead,	all	study	centres	followed	the	local	quality	control	procedures,	including	use	of	10	
phantoms	and	daily	calibration	and	the	results	were	adjusted	for	country	of	testing	to	11	
account	for	possible	systematic	differences.	12	
Future	studies	should	determine	the	reasons	for	the	positive	relationship	between	13	
circulating	sclerostin,	DKK1	and	OPG	with	BMD	in	older	adults,	despite	the	old	having	on	14	
average	higher	circulating	levels	of	these	factors	and	lower	WBMD.		15	
Conclusion	16	
Sclerostin,	DKK1,	OPG	and	OC	were	each	positively	associated	with	WBMD	in	older	adults,	17	
despite	the	average	WBMD	being	lower	and	circulating	DKK1,	OPG	and	sclerostin	being	18	
higher	in	old	than	young.	Multiple	linear	regression	identified	BMI,	circulating	sclerostin	and	19	
whole-body	lean	mass	as	explaining	approximately	14%	of	all	variation	on	WBMD	amongst	20	
older	adults.	21	
	22	
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TABLES	1	
	2	
Table	1.	Participant	descriptive	characteristics.		3	
	 Old	 Young	 p-value	
	 Men	
(n=129)	
Women	
(n=143)	
Men		
(n=82)	
Women	
(n=89)	
Age		 Gender	
Age	
(years)	
74.6±0.3	 74.0±0.3	 23.6±0.3	 23.2±0.3	 <.0005	 	
Height		
(m)	
1.74±0.01	 1.61±0.01	 1.81±0.01	 1.67±0.01	 <.0005	 <.0005	
Body	mass	
(kg)	
78.8±1.0	 65.1±0.8	 75.4±1.2	 62.4±1.0	 <.0005	 .018	
BMI	
(kg/m2)	
25.8±0.3	 25.2±0.3	 23.1±0.3	 22.4±0.3	 .017	 <.0005	
Body	fat	
(kg)	
20.1±0.7	 22.7±0.6	 12.9±0.7	 18.8±0.7	 <.0005	 <.0005	
Lean	mass	
(kg)	
55.9±0.6	
	
40.2±0.5	
	
59.9±0.9	
	
41.4±0.6	
	
<.0005	 <.0005	
Body	fat	
(%)	
25.5±0.6	
	
34.6±0.6	
	
16.6±0.7	
	
29.6±0.7	
	
<.0005	 <.0005	
Lean	mass	
(%)	
71.9±0.6	
	
63.0±0.6	
	
79.8±0.7	
	
67.2±0.7	
	
<.0005	 <.0005	
WBMD	
(g/cm2)	
1.19±0.01	
	
1.04±0.01		 1.25±0.01	
	
1.15±0.01	
	
<.0005	 .001	
WBMD		
(z-score)	
-0.63±0.10	 -1.47±0.11	 0.00±0.11	 0.00±0.11	 <.0005	 <.0005	
	4	
Values	are	mean	±	SEM.	WBMD:	whole-body	bone	mineral	density.	5	
	 	6	
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Table	2.	Circulating	markers	of	bone	remodelling	in	old	and	young,	men	and	women.	1	
	 Old	 Young	 p-value	
	 Men	 Women	 Men	 Women	 Age	 Gender	 Age				x	
Gender	
DKK1	
(pg.mL-1)	
577.0	±	
352-804	
575.3	±	
346-864	
420.6±	
290-627	
494.3	±	
284-703	
<.0005	 .942	 .843	
FGF23	
(pg.mL-1)	
113.5	±	
72-274	
(n=75)	
103.0	±	
64-211	
(n=87)	
122.9.7	±	
87-195	
(n=54)	
141.7	±	
94-225	
(n=60)	
.792	 .316	 .700	
OC			
(pg.mL-1)	
14160.5	±	
9911-18708	
16065.4	±	
11073-19933	
17581.1	±	
13304-21223	
16733.9	±	
12013-20715	
<.0005	 .880	 .036	
OPG	
(pg.mL-1)	
319.2	±	
229-419	
306.9	±	
257-392	
159.4	±	
114-193	
208.5	±	
160-260	
<.0005	 <.0005	 <.0005	
OPN	
(pg.mL-1)	
26590.1	±	
17094-38028	
21350.1	±	
13971-31255	
24822.5	±	
16928-35662	
20877.5	±	
15937-27777	
.700	 .009	 .184	
Sclerostin	
(pg.mL-1)	
5690.3	±	
4348-7556	
4147.6	±	
3349-5159	
3016.1	±	
2079-3932	
2366.0	±	
1923-3134	
<.0005	 <.0005	 .034	
	2	
Values	are	median	±	25th	–	75th	percentiles.	For	FGF23,	the	n	is	less	than	those	given	in	Table	1	due	to	some	3	
samples	having	values	that	were	below	the	level	of	detection.	The	n	for	all	other	analytes	is	the	same	as	shown	4	
in	Table	1.	5	
	6	
	 	7	
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Table	3.	Associations	between	circulating	bone	regulatory	factors	and	whole	body	bone	mineral	density.		1	
Correlation	
with	z-score	
WBMD	
	all	participants	
combined	
Old	 Young	
Adjustment	
models	
1	 2	 1	 2	 1	 2	
DKK1	 r=.107	
p=.026	
r=.129	
p=.008	
r=.167	
p=.007	
r=.174	
p=.005	
r=.263	
p=.001	
r=.282	
p<.0005	
FGF-23	 r=.067	
p=.274	
r=.051	
p=.406	
r=-.095	
p=.235	
r=-.079	
p=.330	
r=-.086	
p=.370	
r=-.130	
p=.182	
OC	 r=-.124	
p=.010	
r=-.083	
p=.088	
r=.150	
p=.015	
r=.187	
p=.003	
r=-.023	
p=.767	
r=-.008	
p=.916	
OPG	 r=-.096	
p=.047	
r=-.039	
p=.419	
r=.209	
p=.001	
r=.254	
p<.0005	
r=.081	
p=.297	
r=.055	
p=.484	
OPN	 r=-.005	
p=.918	
r=-.001	
p=.980	
r=.055	
p=.370	
r=.073	
p=.245	
r=-.120	
p=.124	
r=-.122	
p=.120	
Sclerostin	 r=-.091	
p=.059	
r=-.075	
p=.126	
r=.241	
p<.0005	
r=.240	
p<.0005	
r=.129	
p=.096	
r=.135	
p=.086	
	2	
Data	are	shown	as	spearman’s	rho.	The	circulating	bone	regulatory	factors	were	log-transformed	and	their	z-3	
scores	calculated.	The	p	value	indicates	the	level	of	significance	after	statistical	analysis.	Results	were	adjusted	4	
for	1)	country;	2)	country,	z-score	lean	mass,	z-score	BMI,	self-reported	health	and	supplement	use.	Significant	5	
relationships	are	highlighted	using	bold	text.	6	
	7	
	 	8	
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